Journal
CURRENT NEUROPHARMACOLOGY
Volume 20, Issue 7, Pages 1427-1447Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570159X19666211116142806
Keywords
Parkinson; interaction; food; meal; levodopa; protein; fiber
Categories
Ask authors/readers for more resources
This study investigated the effects of food, beverages, and dietary supplements on the pharmacokinetics and pharmacodynamics of drugs used by Parkinson's disease patients. Recommendations for optimal drug intake with regards to food were provided. Evidence showed positive interactions between levodopa and coffee, fiber, and vitamin C, as well as the potential benefits of a low-fat and protein redistribution diet. Conversely, high-protein diet and ferrous sulfate supplements negatively affected levodopa. Limited data were available for other drugs.
Background: Despite increasing worldwide incidence of Parkinson's disease, the therapy is still suboptimal due to the diversified clinical manifestations, lack of sufficient treatment, the poor adherence in advanced patients, and varied response. Proper intake of medications regarding food and managing drug-food interactions may optimize Parkinson's disease treatment. Objectives: We investigated potential effects that food, beverages, and dietary supplements may have on the pharmacokinetics and pharmacodynamics of drugs used by parkinsonian patients; identified the most probable interactions; and shaped recommendations for the optimal intake of drugs regarding food. Methods: We performed a systematic review in adherence to PRISMA guidelines, and included a total of 81 studies in the qualitative synthesis. Results and Conclusion: We found evidence for levodopa positive interaction with coffee, fiber and vitamin C, as well as for the potential beneficial impact of low-fat and protein redistribution diet. Contrastingly, high-protein diet and ferrous sulfate supplements can negatively affect levodopa pharmacokinetics and effectiveness. For other drugs, the data of food impact are scarce. Based on the available limited evidence, all dopamine agonists (bromocriptine, cabergoline, ropinirole), tolcapone, rasagiline, selegiline in tablets, safinamide, amantadine and pimavanserin can be taken with or without a meal. Opicapone and orally disintegrating selegiline tablets should be administered on an empty stomach. Of monoamine oxidase B inhibitors, safinamide is the least susceptible for interaction with the tyramine-rich food, whereas selegiline and rasagiline may lose selectivity to monoamine oxidase B when administered in supratherapeutic doses. The level of presented evidence is low due to the poor studies design, their insufficient actuality, and missing data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available